Mezigdomide is effective alone and in combination with Menin inhibition in pre-clinical models of KMT2A-r and NPM1c AML
To compare gene expression changes following treatment with two CELMoDs (cereblon E3 ligase modulators) in a Lysine Methyltransferase 2A-rearranged (KMT2A-r) acute myeloid leukemia cell line, we compared gene expression changes after 72 hour of treatment with Iberdomide/CC-220 and Mezigdomide/CC-92480. Overall design: MOLM13 cells were treated for 72 hours with DMSO control, Iberdomide (CC-220) 1 uM, or Mezigdomide (CC-92480) 50 nM with triplicates for each condition.